Results 171 to 180 of about 13,890 (285)

Real‐World Effectiveness and Safety of Recombinant Human Follicle‐Stimulating Hormone (rhFSH) in Infertile Women undergoing Assisted Reproductive Technology (ART): A Korean Nationwide Cohort Study

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 514-523, February 2026.
Despite widespread rhFSH use in infertile women undergoing ART, real‐world comparative data on its effectiveness and safety across different rhFSH types remain limited. Using the HIRA claims database, we included 10,684 women aged 20–39 with infertility (2016–2021) who used only rhFSH in their first in vitro fertilization–embryo transfer (IVF‐ET ...
Joong Yeup Lee   +12 more
wiley   +1 more source

CRISPR‐Cas9‐Generated TXNDC15 c.560delA Homozygous Mouse Model Exhibits Meckel–Gruber Syndrome Phenotype

open access: yesgenesis, Volume 64, Issue 1, February 2026.
ABSTRACT To determine whether TXNDC15 variation causes Meckel–Gruber syndrome (MKS), we assessed the pathogenicity of the frameshift variant c.560delA. A CRISPR–Cas9 generated mouse model carrying the equivalent Txndc15 c.512delA mutation was analyzed at embryonic day 15.5.
Yang Liu   +10 more
wiley   +1 more source

Rhesus testing and anti‐D prophylaxis in RhD‐negative women undergoing first‐trimester abortion—Systematic Review and Opinion

open access: yesInternational Journal of Gynecology &Obstetrics, Volume 172, Issue 2, Page 759-771, February 2026.
Abstract Background The introduction of immunoglobulin G (IgG) anti‐D prophylaxis for Rhesus D (RhD)‐negative women has substantially reduced the incidence of RhD alloimmunization and hemolytic disease of the fetus and newborn in Europe by 85%, transforming fetal health outcomes.
Kristina Gemzell‐Danielsson   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy